

Claims

1. Anti-anti-idiotypic antibody,
c h a r a c t e r i z e d i n t h a t i t
 - (i) reacts with an anti-idiotypic antibody which represents an internal image of the antigen CA125,
 - (ii) is specific for the tumour-associated antigen CA125 and reacts with this antigen, and
 - (iii) mediates an antibody-dependent cellular cytotoxicity against CA125-expressing tumour cells.
2. Anti-anti-idiotypic antibody as claimed in claim 1,
c h a r a c t e r i z e d i n t h a t
it reacts with the monoclonal anti-idiotypic antibody ACA125 produced by the hybridoma 3D5 (DSM ACC2120).
3. Anti-anti-idiotypic antibody as claimed in claim 1 or claim 2,
c h a r a c t e r i z e d i n t h a t
it is produced as a result of a polyclonal immune response by vaccination with an anti-idiotypic antibody which represents an internal image of the antigen CA125.
4. Anti-anti-idiotypic antibody as claimed in claim 1 or claim 2,
c h a r a c t e r i z e d i n t h a t
it is produced recombinantly.

5. Anti-anti-idiotypic antibody as claimed in claim 1 or claim 2,
c h a r a c t e r i z e d i n t h a t
it is produced by hybridoma cells as a monoclonal antibody.
6. Human hybridoma cell line which produces the monoclonal anti-anti-idiotypic antibody as claimed in claim 5.
7. Fragment of an anti-anti-idiotypic antibody as claimed in any one of the claims 1 to 5,
c h a r a c t e r i z e d i n t h a t
it has the binding specificity of the anti-anti-idiotypic antibody.
8. Fragment as claimed in claim 7,
c h a r a c t e r i z e d i n t h a t
it comprises a Fab or F(ab)₂ fragment of the anti-anti-idiotypic antibody optionally coupled to a human Fc part.
9. Pharmaceutical composition comprising an anti-anti-idiotypic antibody as claimed in any one of the claims 1 to 5 or a fragment as claimed in claim 7 or claim 8.
10. Pharmaceutical composition as claimed in claim 8,
c h a r a c t e r i z e d i n t h a t
it additionally contains common pharmaceutical carriers and adjuvants.
11. Pharmaceutical composition as claimed in claim 9 or claim 10 for the treatment and/or prophylaxis of CA125-expressing tumours.

12. Use of an anti-anti-idiotypic antibody as claimed in any one of the claims 1 to 5 or a fragment as claimed in claim 7 or claim 8 for the treatment and/or prophylaxis of CA125-expressing tumours.